Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Arvinas
ARVN
Arvinas
Narrow Protein Degradation Focus Will Exacerbate Downturn Yet Spur Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 18 Analysts
Published
07 Aug 25
Updated
10 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$7.00
1.3% overvalued
intrinsic discount
10 Aug
US$7.09
Loading
1Y
-71.5%
7D
12.7%
Author's Valuation
US$7.0
1.3% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$7.0
1.3% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-323m
373m
2016
2018
2020
2022
2024
2025
2026
2028
Revenue US$47.5m
Earnings US$9.9m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
-7.04%
Pharma revenue growth rate
1.09%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$9.94m
Earnings '28
x
76.33x
PE Ratio '28
=
US$758.42m
Market Cap '28
US$758.42m
Market Cap '28
/
89.81m
No. shares '28
=
US$8.44
Share Price '28
US$8.44
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$6.94
Fair Value '25